Avelumab

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Avelumab is an anti-PD-L1 monoclonal antibody internationally approved for Merkel cell carcinoma and urothelial carcinoma (no Norway license data is available in this evidence pack). The TxGNN model's top-ranked prediction is Human Herpesvirus 8-Related Tumor (e.g. HHV-8-associated Kaposi sarcoma / primary effusion lymphoma), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model output with no corroborating evidence.

Quick Overview

Item	Content
Original Indication	Not licensed in Norway (0 authorizations); internationally approved for Merkel cell carcinoma and urothelial carcinoma
Predicted New Indication	Human Herpesvirus 8-Related Tumor
TxGNN Prediction Score	99.97%
Evidence Level	L5
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a blocking data gap, DG002). Based on the information embedded in this evidence pack, avelumab is an anti-PD-L1 monoclonal antibody, and its efficacy has been established for Merkel cell carcinoma and urothelial carcinoma — both settings where PD-L1-mediated immune evasion drives tumor progression.

The mechanistic rationale for HHV-8-related tumors is that virus-associated malignancies (e.g. Kaposi sarcoma, primary effusion lymphoma) also frequently exploit checkpoint-mediated immune evasion, and blocking PD-L1 could theoretically restore T-cell recognition of viral tumor antigens. However, this population commonly presents with concurrent HIV infection or other immunosuppression, which substantially complicates the risk-benefit profile of checkpoint blockade and is not addressed anywhere in this dataset.

This remains a mechanism-only extrapolation: there is no PD-L1 expression data, no preclinical model, and no clinical or literature evidence specific to HHV-8-related tumors to support the prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Cytotoxicity

Avelumab is an antineoplastic agent (immune checkpoint inhibitor class), so this section is included.

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-L1 monoclonal antibody; not conventional cytotoxic chemotherapy)
Myelosuppression Risk	Low — checkpoint inhibitors are not typically myelosuppressive; toxicity is primarily immune-related (irAEs) rather than hematologic
Emetogenicity Classification	Low
Monitoring Items	Thyroid, liver and renal function; infusion-related reaction monitoring; surveillance for immune-related adverse events (colitis, pneumonitis, endocrinopathies)
Handling Protection	No special cytotoxic-drug handling protocol required; standard biologic infusion precautions apply

Note: No drug-specific toxicity dataset was available (DrugBank toxicity fields empty); the above reflects general class characteristics of PD-L1 inhibitors and should be confirmed against the official package insert once available.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all flagged as data gaps or "not found" in this evidence pack — DG001 is a blocking gap.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Human Herpesvirus 8-Related Tumor) has an L5 evidence level — no clinical trials, no literature, and a plausible but unverified mechanistic rationale complicated by the frequent HIV/immunosuppression comorbidity in this population. This does not meet the threshold to advance to safety screening (S1).

To proceed, the following is needed:

Official label data (warnings/contraindications) from TFDA or equivalent regulatory source — currently blocking (DG001)
Formal MOA documentation from DrugBank or product label (DG002)
Preclinical or biomarker evidence of PD-L1 expression in HHV-8-associated tumors
Safety assessment specific to concurrent HIV/immunosuppressed populations before any clinical exploration

Note: Among the 10 candidates in this pack, ranks 9–10 (prostatic urethra urothelial carcinoma; kidney pelvis sarcomatoid transitional cell carcinoma) show comparatively stronger mechanistic grounding — both are histological/anatomical extensions of avelumab's already-approved urothelial carcinoma indication, and rank 10 has one completed real-world observational trial (NCT05431777, L3). These may warrant prioritization over the top-ranked HHV-8 prediction for further evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.